AADI - Aadi Bioscience, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Aadi Bioscience, Inc.

17383 Sunset Boulevard
Suite A250
Pacific Palisades, CA 90272
United States
424 473 8055

Full-time employees80

Key executives

NameTitlePayExercisedYear born
Dr. Neil P. Desai Ph.D.Founder, Sec. & Exec. Chairman1.12MN/A1965
Dr. Loretta M. Itri F.A.C.P., M.D.Chief Medical Officer805.85kN/A1950
Mr. Scott M. Giacobello CPAInterim CEO, Pres, CFO & TreasurerN/AN/A1970
Ms. Marcy GrahamSVP of Investor Relations & Corp. CommunicationsN/AN/A1967
Mr. Stephen M. Rodin J.D.Sr. VP of Legal & Gen. CounselN/AN/A1976
Mr. Raymond G. SteitzSr. VP of HR & Chief HR OfficerN/AN/A1959
Mr. Bryan BallChief Quality Officer & Sr. VP of Manufacturing OperationsN/AN/A1970
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Corporate governance

Aadi Bioscience, Inc.’s ISS governance QualityScore as of 1 June 2023 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.